Molecular docking and 3D-QSAR studies of 2-substituted 1-indanone derivatives as acetylcholinesterase inhibitors

Acta Pharmacologica Sinica

Volumn 28, Issue 12, 2007, Pages 2053-2063

  Shen, Liang Liang ^a   Liu, Gui Xia ^a   Tang, Yun ^a  

^a EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

3D QSAR; Acetyl cholinesterase; Alzheimer's disease; Molecular docking

Indexed keywords

ACETYLCHOLINESTERASE; CHOLINESTERASE INHIBITOR; DONEPEZIL; INDANONE DERIVATIVE;

ARTICLE; BINDING AFFINITY; COMPARATIVE MOLECULAR FIELD ANALYSIS; COMPARATIVE MOLECULAR SIMILARITY INDICES ANALYSIS; DRUG CONFORMATION; DRUG MECHANISM; DRUG POTENCY; DRUG SPECIFICITY; DRUG STRUCTURE; ENZYME ACTIVE SITE; ENZYME INHIBITION; HYDROPHOBICITY; MOLECULAR DOCKING; PREDICTION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; VALIDATION PROCESS;

ACETYLCHOLINESTERASE; CHOLINESTERASE INHIBITORS; INDANS; LIGANDS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 36649032715     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1111/j.1745-7254.2007.00664.x     Document Type: Article

References (35)

1. Lahiri DK, Farlow MR, Greig NH, Sambamurti K. Current drug targets for Alzheimer's disease treatment. Drug Dev Res 2002 56:267 81.
2. Silman I, Sussman JL. Acetylcholinesterase: 'classical' and 'non-classical' functions and pharmacology. Curr Opin Pharmacol 2005 5:293 302.
3. Raves ML, Harel M, Pang YP, Silman I, Kozikowski AP, Sussman JL. Structure of acetylcholinesterase complexed with the nootropic alkaloid, (-)-huperzine A. Nat Struct Biol 1997 4:57 63.
4. Kryger G, Silman I, Sussman JL. Structure of acetylcholinest-erase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs. Struct 1999 7:297 307.
5. Harel M, Schalk I, Ehret-Sabatier L, Bouet F, Goeldner M, Hirth C, et al. Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase. Proc Natl Acad Sci USA 1993 90:9031 5.
6. Harel M, Quinn DM, Nair HK, Silman I, Sussman JL. The X-ray structure of a transition state analog complex reveals the molecular origins of the catalytic power and substrate specificity of acetylcholinesterase. J Am Chem Soc 1996 118:2340 6.
7. Greenblatt HM, Kryger G, Lewis T, Silman I, Sussman JL. Structure of acetylcholinesterase complexed with (-)-galanthamine at 2.3 Å resolution. FEBS Lett 1999 463:321 6.
8. Ravelli RB, Raves ML, Ren Z, Bourgeois D, Roth M, Kroon J, et al. Static Laue diffraction studies on acetylcholinesterase. Acta Crystallogr D Biol Crystallogr 1998 54:1359 66.
9. Inestrosa NC, Alvarez A, Perez CA, Moreno RD, Vicente M, Linker C, et al. Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Neuron 1996 16:881 91.
10. Bartolini M, Bertucci C, Cavrini V, Andrisano V. Beta-amyloid aggregation induced by human acetylcholinesterase: inhibition studies. Biochem Pharmacol 2003 65:407 16.
11. Munoz-Muriedas J, Lopez JM, Orozco M, Luque FJ. Molecular modelling approaches to the design of acetylcholinesterase inhibitors: new challenges for the treatment of Alzheimer's disease. Curr Pharm Des 2004 10:3131 40.
12. Du DM, Carlier PR. Development of bivalent acetylcholinest-erase inhibitors as potential therapeutic drugs for Alzheimer's disease. Curr Pharm Des 2004 10:3141 56.
13. Soreq H, Seidman S. Acetylcholinesterase-new roles for an old actor. Nat Rev Neurosci 2001 2:294 302.
14. Sheng R, Lin X, Li J, Jiang Y, Shang Z, Hu Y. Design, synthesis, and evaluation of 2-phenoxy-indan-1-one derivatives as acetylcholinesterase inhibitors. Bioorg Med Chem Lett 2005 15:3834 7.
15. Sheng R, Lin X, Li J, Jiang Y, Hu Y. Design, synthesis, and evaluation of 2-benzylidene-indan-1-one and 2-benzyl-indan-1-one derivatives as acetylcholinesterase inhibitors. In:Lee HZ, Hu YZ, editors. Proceedings of the 7th China-Japan Joint Symposium on Drug Design and Development; 22-26 Sep 2005, Hangzhou, China. Asian Federation of Medicinal Chemistry. Hangzhou: China 2005. p31 p33.
16. Akula N, Lecanu L, Greeson J, Papadopoulos V. 3D QSAR studies of AChE inhibitors based on molecular docking scores and CoMFA. Bioorg Med Chem Letter 2006 16:6277 80.
17. SYBYL (Computer program). Version 7.0. St Louis, MO:Tripos Associates 2004.
18. Clark M, Cramer RDI, van Opdenbosch N. Validation of the general purpose Tripos 5.2 force field. J Comput Chem 1989 10:982 1012.
19. Gasteiger J, Marsili M. Iterative partial equalization of orbital electronegativity: a rapid access to atomic charges. Tetrahedron 1980 36:3219 28.
20. ACD/Labs Online (I-Lab), pKa caculation. [cited 2006 Aug 6]. Available from URL:http://ilab.acdlabs.com/.
21. Gilson MK, Straatsma TP, McCammon JA, Ripoll DR, Faerman CH, Axelsen PH, et al. Open "back door" in a molecular dynamics simulation of acetylcholinesterase. Science 1994 263:1276 8.
22. Wlodek ST, Antosiewicz J, McCammon JA. Prediction of titration properties of structures of a protein derived from molecular dynamics trajectories. Protein Sci 1997 6:373 82.
23. Weiner SJ, Kollman PA, Case DA, Singh C, Ghio G, Alagona S, et al. A new force field for molecular mechanical simulation of nucleic acids and proteins. J Am Chem Soc 1984 106:765 84.
24. Jones G, Willett P, Glen RC, Leach AR, Taylor R. Development and validation of a genetic algorithm for flexible docking. J Mol Biol 1997 267:727 48.
25. Eldridge MD, Murray CW, Auton TR, Paolini GV, Mee RP. Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes. J Comput Aided Mol Des 1997 11:425 45.
26. Guo J, Hurley MM, Wright JB, Lushington GH. A docking score function for estimating ligand-protein interactions: application to acetylcholinesterase inhibition. J Med Chem 2004 47:5492 500.
27. Cramer RD III., Patterson DE, Bunce JD. Comparative molecular field analysis. 1. Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc 1988 110:5959 67.
28. Klebe G, Abraham U, Mietzner T. Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J Med Chem 1994 37:4130.
29. Xie Q, Tang Y, Li W, Wang XH, Qiu ZB. Investigation of the binding mode of (-)-meptazinol and bis-meptazinol derivatives on acetylcholinesterase using a molecular docking method. J Mol Model 2006 12:390 7.
30. Sugimoto H, Yamanishi Y, Iimura Y, Kawakami Y. Donepezil hydrochloride (E2020) and other acetylcholinesterase inhibitors. Curr Med Chem 2000 7:303 39.
31. Kaur J, Zhang MQ. Molecular modelling and QSAR of reversible acetylcholines-terase inhibitors. Curr Med Chem 2000 7:273 94.
32. Golbraikh A, Tropsha A. Beware of q2. J Mol Graph Model 2002 20:269 76.
33. Shi LM, Fang H, Tong W, Wu J, Perkins R, Blair RM, et al. QSAR models using a large diverse set of estrogens. J Chem Inf Comput Sci 2001 41:186 95.
34. Zuo Z, Luo X, Zhu W, Shen J, Shen X, Jiang H, et al. Molecular docking and 3D-QSAR studies on the binding mechanism of statine-based peptidomimetics with beta-secretase. Bioorg Med Chem 2005 13:2121 31.
35. Schrödinger (Computer program). Version 2006. Portland, OR:Schrödinger, LLC 2006.